Clinical trials: Papilloma Virus, Human
Human Papilloma Virus
A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls
Cervical cancer is the most common cancer in women aged 15-44 years in East Africa, and mortality rates are very high. HPV vaccines are most effective if given to girls who have not yet acquired HPV infection.
- Trial name
- DoRIS (NCT02834637)
- Testing
- bivalent HPV vaccine, nonavalent HPV vaccine
- Where
- Tanzania
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Cervical Intraepithelial Neoplasia Grade 2/3, Neoplasm Cervix
Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus
The European VALHUDES study is a Clinical Performance /Diagnostic Test Accuracy Study that aims to evaluate whether HPV testing with new assays performed on self-samples, collected by means of a vaginal and a urine collection…
- Conditions
- Cervical Intraepithelial Neoplasia Grade 2/3, Neoplasm Cervix, Carcinoma in Situ, Carcinoma Cervix Uterine
- Trial name
- EU-VALHUDES (NCT04312737)
- Testing
- Self-Collecting Devices, In Vitro Diagnostic Assays
- Where
- 6 sites in Ireland, Italy and 1 more
- Volunteers
- 600 people
- Sponsor
- Hiantis Srl
Head Neck Cancer, Oropharyngeal Neoplasms
Human Papillomavirus Association and Genomic Exploration in Head-Neck Squamous Cell Carcinomas
Head and neck squamous cell carcinoma (HNSCC) represents a significant public health burden in Bangladesh with a high incidence and mortality rate.
- Trial name
- HPV & HNSCC (NCT06642324)
- Testing
- Histopathology, Immunohistochemistry, Real-Time PCR, Sequencing
- Where
- Bangladesh
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Nonneoplastic Condition, Precancerous Condition
Human Papilloma Virus Infection in HIV-Positive Indian Men Who Have Sex With Men
RATIONALE: Gathering information about human papilloma virus (HPV) infection in HIV-positive men who have sex with men may help doctors learn more about the disease.
- Trial name
- NCT00919997
- Testing
- DNA analysis, polymerase chain reaction, fluorescence activated cell sorting
- Where
- United States
- Volunteers
- 302 people
- Sponsor
- AIDS Malignancy Consortium
Cancer of the Uterine Cervix
Feasibility and Acceptability of Offering Self-sampling to Non-attendees in Primary Care
The purpose of this study is to determine whether human-papillomavirus (HPV) self-sampling can be used as a primary screening test for unscreened women.
- Trial name
- DEPIST (NCT02698423)
- Testing
- Cobas HPV DNA Test, Papanicolau test
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
HSIL, HSIL of Cervix
Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection
This study evaluates the use of topical ABI-1968 cream, in the treatment of cervical precancerous lesions in adult women.
- Conditions
- HSIL, HSIL of Cervix, High-Grade Squamous Intraepithelial Lesions, High-grade Cervical Intraepithelial Neoplasia
- Trial name
- NCT03239223
- Testing
- ABI-1968
- Where
- 9 sites in United States, Australia
- Volunteers
- 16 people
- Sponsor
- Antiva Biosciences
HPV, Self-sampling
Clinical Performance of Urine HPV Testing in Males
Human papillomavirus (HPV) infection is one of the most prevalent viral infections of the genital tract, primarily transmitted through sexual contact.
- Conditions
- HPV, Self-sampling, Male
- Trial name
- NCT06671210
- Testing
- Urine and vaginal swab self-control
- Where
- 2 sites in China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
HPV Infection, CIN1
Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions
A Phase 1b/2 multi-centre study evaluating the safety, efficacy and immunogenicity of prime-boost vaccines ChAdOx1-HPV and MVA-HPV in women with HPV related low grade cervical lesions.
- Trial name
- NCT04607850
- Testing
- ChAdOx1-HPV, MVA-HPV
- Where
- 16 sites in Belgium, Estonia and 1 more
- Volunteers
- 108 people
- Sponsor
- Barinthus Biotherapeutics
High-grade Squamous Intraepithelial Lesions of the Cervix Associated With Human Papillomavirus (HPV) Type 16 and/or HPV Type 18 Infection
Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL)
The goal of this study is to learn about the safety, tolerability, immunogenicity and preliminary efficacy of BBM-C101 injection in patients with High-Grade Squamous Intraepithelial Lesion of the cervix.
- Trial name
- NCT07668960
- Testing
- BBM-C101
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Mianyi Biopharmaceutical Co., Ltd.
Head and Neck Cancer, Head and Neck Neoplasms
Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
Background: Some people who get head and neck cancer will need surgery to treat their cancer. Research suggests that immunotherapy drugs may help fight head and neck cancer if given before surgery.
- Trial name
- NCT04247282
- Testing
- M7824, N803, TriAd vaccine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
HPV
Human Papilloma Virus (HPV) Knowledge and Attitudes and the Role of (SES) Socioeconomic Status and Ethnicity
This is a survey study to assess the vaccination knowledge and attitudes of women in an inner city Gynecology clinic. Results of this study will help determine which factors influence vaccination knowledge and attitudes.
- Trial name
- NCT01105000
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Human Papillomavirus-Related Malignant Neoplasm
A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ
This is an open-label and triple cohort study of the safety and efficacy of TALEN and CRISPR/Cas9 to possibly treat HPV Persistency and human cervical intraepithelial neoplasiaⅠwithout invasion.
- Trial name
- NCT03057912
- Testing
- TALEN, CRISPR/Cas9
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Lichen Planus
Implication of Human Papillomavirus (HPV) in Lichen Physiopathology in Human (HPVLichen)
Lichen planus is a chronic cutaneous and mucosal disease characterized by the infiltration of cluster of differentiation (CD) CD8 T lymphocytes, localized under the basal membrane and associated with apoptosis of basal…
- Trial name
- HPVLichen (NCT02761122)
- Testing
- Human biological samples
- Where
- 3 sites in France
- Volunteers
- 21 people
- Sponsor
- Institut Pasteur
Infections, Papillomavirus
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand
This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 008/580299 and received the control vaccine (Hepatitis A vaccine).
- Trial name
- NCT00849381
- Testing
- GSK580299, GSK Biological's HPV vaccine
- Where
- 9 sites in Brazil, Taiwan and 1 more
- Volunteers
- 1,239 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cutaneous Warts, Human Papilloma Virus (HPV)
Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts
This study compares the effectiveness and safety of two different intralesional treatments for cutaneous warts: a combination of furosemide and digoxin versus polidocanol.
- Trial name
- NCT07307131
- Testing
- Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml), Intralesional polidocanol 2%
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Benha University
Condylomata Acuminata, Papillomavirus Infections
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
This is a Phase 2, double-blind, placebo-controlled study to determine the dose regimen, safety, tolerability, and efficacy of VP-102 in subjects with External Genital Warts (EGW).
- Conditions
- Condylomata Acuminata, Papillomavirus Infections, Skin Diseases, Viral, Skin Diseases, Infectious
- Trial name
- CARE-1 (NCT03981822)
- Testing
- VP-102 and applicator
- Where
- 4 sites in United States
- Volunteers
- 105 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Hepatitis B, Human Papilloma Virus
Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.
Aim: The main goal of this quantitative epidemiological observational study is to determine the prevalence of Human Papilloma Virus (HPV) infection and Hepatitis B (Hep B) immunity amongst women of childbearing age.
- Conditions
- Hepatitis B, Human Papilloma Virus, Mental Health Issue, Cancer Liver
- Trial name
- NCT06786429
- Testing
- Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy
- Volunteers
- 2,140 people, healthy volunteers welcome
- Sponsor
- Eunice Dube
Head and Neck Cancer
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
This research study is studying lowering the standard dose of radiation and chemotherapy after surgery, to minimize the side effects and improve the quality of life.
- Trial name
- NCT03875716
- Testing
- Radiation therapy
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Dana-Farber Cancer Institute
HPV Infection, HPV 16 Infection
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
The EQUIP Study is testing whether high-risk human papillomavirus (hrHPV), the virus that causes most cervical cancers, can be accurately detected from menstrual blood collected at home.
- Conditions
- HPV Infection, HPV 16 Infection, High Risk HPV, Cervical Cancer Screening
- Trial name
- EQUIP (NCT07281599)
- Testing
- Q-Pad hrHPV Test System
- Where
- 3 sites in United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Qurasense
Mucoviscidosis
Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis (VACCIN-HPV-MUC2)
Background The main risk factor for cervical cancer is the infection by human papillomavirus (HPV). Vaccination against HPV, offered to all girls aged 11 to 14 is an effective method of prevention against cervical pathology.
- Trial name
- NCT03653377
- Testing
- Self administrated questionnaire
- Where
- 7 sites in France
- Volunteers
- 81 people
- Sponsor
- Hospices Civils de Lyon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.